| HOME >> MEDICINE >> TECHNOLOGY |
Core analysis, 2008-14 51
Expiry analysis, 2008-14 53
Launch/core/expiry configuration, 2008-14 54
Molecule type analysis 55
Externalization analysis 58
Chapter 6 Company financials 61
Key findings 61
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 62
Operating costs and profit analysis 64
Operating costs and profit analysis, 2002-08 65
Operating cost ratio and profit margin analysis, 2002-08 67
Operating cost ratio and profit margin analysis, 2008-14 68
Operating costs and profit analysis, 2008-14 69
Chapter 7 Key products and competitors 70
Key findings 70
Overview 71
Oncology 72
Avastin 72
Overview 72
Sales forecast 73
First-to-market VEGF inhibitor 73
Indication broadening expected to drive sales 73
Key competitors 73
Herceptin 75
Overview 75
Sales forecast 76
What is Herceptin? 76
Key competition from Tykerb in the long term 77
Rituxan 78
Overview 78
Sales forecast 79
What is Rituxan? 79
Indication-broadening to promote sustained sales expansion 79
Rituxan currently faces little competition and steady sales are anticipated 80
Neutrogin 81
Overview 81
Sales forecast 82
Internally developed Neutrogin is central to Chugai's historical growth 82
Biosimilar threat to EU market 83
Tarceva 84
Overview 84
Sales forecast 85
What is Tarceva? 85
Key competitors 85
Hematology 87
Epogin 87
Overview 87
Sales forecast 88
Kirin's Espo and follow-on Nesp pose key competition 8
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |